Email Contact Phone Company Visit Website

Location Office

Kungsgatan 36
Stockholm
SE

NASDAQ OMX New York Head Office

One Liberty Plaza
New York
NY
US

NASDAQ OMX Stockholm Office

Tullvaktsvägen 15
Stockholm
SE

NASDAQ OMX Rockville Office

805 King Farm Boulevard 1st and 2nd floor
Rockville
MD
US

NASDAQ OMX London Office

Woolgate Exchange, 25 Basinghall Street, City of London
London
GB

NASDAQ OMX New York Office

Marketsite 4 Times Square
New York
NY
US

NASDAQ OMX Hong Kong Office

Room 1207-8, 12/F Man Yee Building 68 Des Voeux Road Central Hong Kong
Hong Kong
HK

NASDAQ OMX Singapore Office

20 Collyer Quay, #17-01
Singapore
SG

NASDAQ OMX Chicago Office

One North Wacker Drive Suite 3600
Chicago
IL
US

NASDAQ OMX Belgium Office

Avenue de Cortenbergh 116
Brussels
BE

NASDAQ OMX Dubai Office

Dubai World Trade Centre Sheikh Zayed Road
Dubai
AE

NASDAQ OMX Tokyo Office

1F, Kojimachi Square Building Nibancho, 3 Chiyoda-ku, Tokyo
Tokyo
JP

NASDAQ OMX Boston Office

100 Franklin St
Boston
MA
US

Location Office

Level 17-19, 110 Bishopsgate
London
GB

Telephone

212 231 5018

Contact

Todd A Swearingen
[email protected]
Back to all NASDAQ OMX announcements

Semi-Annual Changes to the NASDAQ Biotechnology Index

The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index® (Nasdaq:NBI), which will become effective prior to market open on Monday, May 20, 2013.

The following eleven securities will be added to the Index: ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD); Albany Molecular Research, Inc. (Nasdaq:AMRI); Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC); Clovis Oncology, Inc. (Nasdaq:CLVS); Furiex Pharmaceuticals, Inc. (Nasdaq:FURX); Hyperion Therapeutics, Inc. (Nasdaq:HPTX); NewLink Genetics Corporation (Nasdaq:NLNK); Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX); Repligen Corporation (Nasdaq:RGEN); Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP); and Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP).

The Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November.

As a result of the re-ranking, the following four securities will be removed from the Index: Affymax, Inc. (Nasdaq:AFFY); BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX); Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT); and Savient Pharmaceuticals Inc. (Nasdaq:SVNT).

The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.